Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Cost-effectiveness of chronic hepatitis C treatment in Spain].

Gastroenterologia y hepatologia - 1 Jan 2000

Haj-Ali Saflo Okba, Hernández Guijo Jesús Miguel

Abstract excerpt

In this study we evaluated the pharmacologic costs of hepatitis C treatment, considering recommendations on both the duration of therapy and sustained virological response. With this aim, we analyzed relevant scientific articles published in the previous 10 years, considering the most common genotypes present in Spain. In this analysis, we estimated overall costs to be 1,636,524.58-1,761,365.73 euro and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Cost-Benefit Analysis
Share to Genotype

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis C, Chronic

Source

Identifiers

PMID: 19615787
DOI: 10.1016/j.gastrohep.2009.01.181

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Cost-effectiveness of chronic hepatitis C treatment in Spain].PMID 19615787Read ↗

Costs and outcomes of treating chronic hepatitis C patients in routine care - results from a nationwide multicenter trial.Semantic proximity Read ↗

Pharmacoeconomic analysis of the treatment of chronic hepatitis C with peginterferon alfa-2a or peginterferon alfa-2b plus ribavirin in Spain.Semantic proximity Read ↗

[CLINICAL AND ECONOMIC ANALYSIS OF ALTERNATIVE SCHEMES OF ANTIVIRAL THERAPY OF CHRONIC HEPATITIS C GENOTYPE 1 IN PATIENTS WHO DID NOT ANSWER TO THE PRIOR THERAPY, IN THE RUSSIAN FEDERATION].Semantic proximity Read ↗

Boceprevir for Chronic Genotype 1 Hepatitis C Virus in the Current Health Care Setting in Greece: A Cost-effectiveness Analysis.Semantic proximity Read ↗

Micro-costing analysis of guideline-based treatment by direct-acting agents: the real-life case of hepatitis C management in Brazil.Semantic proximity Read ↗

Treatment guidelines for Hepatitis C in Spain.Semantic proximity Read ↗

Present, old and future strategies for anti-HCV treatment in patients infected by genotype-1: estimation of the drug costs in the Calabria Region in the era of the directly acting antivirals.Semantic proximity Read ↗

Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.Semantic proximity Read ↗

Cost-effectiveness analysis is a mandatory strategy for health systems: evidence from a study involving therapies for hepatitis C.Semantic proximity Read ↗

Direct-Acting Antiviral Agents for Patients With Hepatitis C Virus Genotype 1 Infection Are Cost-Saving.Semantic proximity Read ↗

Non-pharmacologic direct cost of a simplified strategy with glecaprevir/pibrentasvir for 8 weeks in naïve non-cirrhotic patients with hepatitis C implemented in clinical practice. The Just SIMPLE Study.Semantic proximity Read ↗

A real-world impact of cost-effectiveness of pegylated interferon/ribavarin regimens on treatment-naïve chronic hepatitis C patients in Taiwan.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.